DOCSLIB.ORG

Therapeutic Antibody

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Antibody www.creativebiolabs.net THERAPEUTIC ANTIBODY Tel: 1-631-871-5806 Fax: 1-631-207-8356 45-1 Ramsey Road, Shirley, NY 11967, USA DBA Italia s.r.l. Via Umbria, 10, 20090 Segrate (Milan) Tel: +39 02 26922300 Fax:+39 02 26923535 DBA Italia s.r.l. email: [email protected] Via Umbria, 10, 20090 Segrate (Milan) Tel: +39 02 26922300 Fax:+39 02 26923535 email: [email protected] Products List Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer a full range of therapeutic antibodies currently available for research of a wide variety of diseases. We guarantee generated endotoxin free antibodies are fully functional and ready to use in animal- based assays and clinical trials. I Autoimmune and Inflammatory Diseases Antibody Cat. No Product Name Related Disease Name/Clone Anti-Human ITGA4+ITGB7 TAB-H02 Abrilumab Ulcerative colitis Therapeutic Antibody Anti-Human TNF Therapeutic Adalimumab Juvenile Idiopathic Arthritis TAB-010 Antibody TAB-717 Anti-APP Therapeutic Antibody Aducanumab Alzheimer's disease Anti-Human SOST Therapeutic Postmenopausal women TAB-115 Antibody Blosozumab osteoporosis Anti-Human IL12+IL23 Briakinumab Crohn's disease TAB-103 Therapeutic Antibody Anti-Human IL17RA Therapeutic Brodalumab Psoriatic arthritis TAB-134 Antibody Anti-Human MCP-1 Therapeutic Carlumab Immune disease TAB-117 Antibody Anti-Human CD4 Therapeutic Cedelizumab Allograft rejection TAB-107 Antibody Anti-Human IL6 Therapeutic TAB-094 Clazakizumab Crohn's disease Antibody Anti-Human CD4 Therapeutic TAB-260 Tregalizumab Psoriasis Antibody Anti-Human ITGA4 Therapeutic TAB-022 Natalizumab Multiple sclerosis Antibody Anti-Human CD11a Therapeutic TAB-108 Odulimomab Allograft rejection Antibody TAB-772 Anti-CD20 Therapeutic Antibody Ocrelizumab Multiple sclerosis Anti-Human IGHE Therapeutic TAB-007 Omalizumab Allergic asthma Antibody Anti-Human IL4 Therapeutic TAB-221 Pascolizumab Allergy Antibody www.creativebiolabs.net 4 / 30 Products List II Cancers Antibody Cat. No Product Name Indications Name/Clone TAB-731 Anti-GD2 Therapeutic Antibody Dinutuximab Neuroblastoma TAB-114 Anti-Human CA-125 Therapeutic Antibody Abagovomab Ovarian cancer Colorectal cancers, TAB-H01 Anti-Human ITGAV Therapeutic Antibody Abituzumab metastatic TAB-106 Anti-Human EPCAM Therapeutic Antibody Adecatumumab Prostate and breast cancer TAB-133 Anti-Human CD20 Therapeutic Antibody Afutuzumab Lymphoma TAB-201 Anti-Human Mesothelin Therapeutic Antibody Amatuximab Pancreatic cancers Chronic lymphocytic TAB-150 Anti-Human HLA DR beta Therapeutic Antibody Apolizumab leukemia Colorectal cancers, TAB-011 Anti-Human VEGF Therapeutic Antibody Bevacizumab metastatic Bivatuzumab TAB-H09 Anti-Human CD44 Therapeutic Antibody Squamous cell carcinoma mertansine TAB-728 Anti-CD19 Therapeutic Antibody Blinatumomab Acute lymphocytic leukemia TAB-H11 Anti-Human NOTCH1 Therapeutic Antibody Brontictuzumab Lymphoma TAB-078 Anti-Human IGF1 Receptor Therapeutic Antibody Cixutumumab Non-small cell lung cancers TAB-H14 Anti-Human GPC3 Therapeutic Antibody Codrituzumab Hepatocellular carcinoma TAB-203 Anti-Human DR5 Therapeutic Antibody Conatumumab Non-small cell lung cancers TAB-144 Anti-Human CD30 Therapeutic Antibody Iratumumab Hodgkin's lymphoma TAB-764 Anti-ganglioside GD3 Therapeutic Antibody Mitumomab Small cell lung carcinoma TAB-H56 Anti-Human MUC1 Therapeutic Antibody Pemtumomab Cancers TAB-209 Anti-Human IGF1 Receptor Therapeutic Antibody Robatumumab Blood cancers TAB-877 Anti-Human Tenascin C/TNC Therapeutic Antibody Tenatumomab Cancers TAB-206 Anti-Human CTLA4 Therapeutic Antibody Ticilimumab Cancers TAB-005 Anti-Human ErbB2 Therapeutic Antibody Trastuzumab Breast cancers Chronic lymphocytic TAB-207 Anti-Human CD20 Therapeutic Antibody Ublituximab leukemia TAB-880 Anti-Human Frizzled receptor Therapeutic Antibody Vantictumab Solid tumors TAB-264 Anti-Human NRP1 Therapeutic Antibody Vesencumab Solid tumors TAB-715 Anti-CTAA16.88 Therapeutic Antibody Votumumab Colorectal tumors TAB-H35 Anti-Human EGFR Therapeutic Antibody Futuximab Colorectal cancers TAB-033 Anti-Human CEACAM5 Therapeutic Antibody Labetuzumab Colorectal cancers www.creativebiolabs.net Products List III Other Diseases Antibody Cat. No Product Name Indications Name/Clone Anti-C. difficile Toxin A Therapeutic Clostridium difficile infectious TAB-716 Actoxumab Antibody diarrhea TAB-718 Anti- -Therapeutic-Antibody Afelimomab Sepsis TAB-242 Anti-Human RTN-4 Therapeutic Antibody Atinumab Spinal cord injury Hemolytic disease of the TAB-149 Anti-Human RHD Therapeutic Antibody Atorolimumab newborn Anti-Human Phosphatidylserine Bavituximab Viral infections TAB-175 Therapeutic Antibody Clostridium difficile infectious TAB-725 Anti-C. diff toxin B Therapeutic Antibody Bezlotoxumab diarrhea TAB-H10 Anti-Human PCSK9 Therapeutic Antibody Bococizumab Hypercholesterolemia Anti-Human IL1 beta Therapeutic Gevokizumab Cardiovascular disease TAB-161 Antibody TAB-734 Anti-TFPI Therapeutic Antibody Concizumab Hemophilia Anti-Human TGF beta 2 Therapeutic Lerdelimumab Glaucoma surgery TAB-100 Antibody TAB-775 Anti-oxLDL Therapeutic Antibody Orticumab Atherosclerosis TAB-009 Anti-RSV Therapeutic Antibody Palivizumab Respiratory Syncytial Virus Cytomegalovirus (CMV) TAB-16 Anti-CMV Therapeutic Antibody Sevirumab infections Anti-Human Myostatin/GDF8 Therapeutic Stamulumab Muscular dystrophy TAB-888 Antibody TAB-111 Anti-Human NGF Therapeutic Antibody Tanezumab Pain TAB-159 Anti-Human CD3 Therapeutic Antibody Teplizumab Type 1 diabetes Anti-E. coli Shiga-like toxin II B Urtoxazumab Diarrhoea caused by E. coli TAB-157 Therapeutic Antibody More products, please visit our website: http://www.creativebiolabs.net www.creativebiolabs.net .
Load more

Recommended publications
  • Old and New Challenges in Uveitis Associated with Behçet's Disease
    Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage.
    [Show full text]
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Malignant B Lymphocyte Survival in Vivo CD22 Ligand Binding Regulates Normal
    The Journal of Immunology CD22 Ligand Binding Regulates Normal and Malignant B Lymphocyte Survival In Vivo1 Karen M. Haas, Suman Sen, Isaac G. Sanford, Ann S. Miller, Jonathan C. Poe, and Thomas F. Tedder2 The CD22 extracellular domain regulates B lymphocyte function by interacting with ␣2,6-linked sialic acid-bearing ligands. To understand how CD22 ligand interactions affect B cell function in vivo, mouse anti-mouse CD22 mAbs were generated that inhibit CD22 ligand binding to varying degrees. Remarkably, mAbs which blocked CD22 ligand binding accelerated mature B cell turnover by 2- to 4-fold in blood, spleen, and lymph nodes. CD22 ligand-blocking mAbs also inhibited the survival of adoptively transferred normal (73–88%) and malignant (90%) B cells in vivo. Moreover, mAbs that bound CD22 ligand binding domains induced significant CD22 internalization, depleted marginal zone B cells (82–99%), and reduced mature recirculating B cell numbers by 75–85%. The CD22 mAb effects were independent of complement and FcRs, and the CD22 mAbs had minimal effects in CD22AA mice that express mutated CD22 that is not capable of ligand binding. These data demonstrate that inhibition of CD22 ligand binding can disrupt normal and malignant B cell survival in vivo and suggest a novel mechanism of action for therapeutics targeting CD22 ligand binding domains. The Journal of Immunology, 2006, 177: 3063–3073. D22 is a B cell-specific glycoprotein of the Ig superfam- cell surface CD22, IgM, and MHC class II expression on mature B ily expressed on the surface of maturing B cells coinci- cells, whereas normal BCR signaling and Ca2ϩ mobilization are dent with IgD expression (1, 2).
    [Show full text]
  • Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials
    Wu et al. Cancer Drug Resist 2018;1:204-18 Cancer DOI: 10.20517/cdr.2018.16 Drug Resistance Review Open Access Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials Xiaorong Wu, Thomas Kilpatrick, Ian Chau Department of Medical oncology, Royal Marsden Hospital NHS foundation trust, Sutton SM2 5PT, UK. Correspondence to: Dr. Ian Chau, Department of Medical Oncology, Royal Marsden Hospital NHS foundation trust, Downs Road, Sutton SM2 5PT, UK. E-mail: [email protected] How to cite this article: Wu X, Kilpatrick T, Chau I. Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials. Cancer Drug Resist 2018;1:204-18. http://dx.doi.org/10.20517/cdr.2018.16 Received: 31 Aug 2018 First Decision: 8 Oct 2018 Revised: 13 Nov 2018 Accepted: 16 Nov 2018 Published: 19 Dec 2018 Science Editors: Elisa Giovannetti, Jose A. Rodriguez Copy Editor: Cui Yu Production Editor: Huan-Liang Wu Abstract Gastrointestinal (GI) cancers represent the leading cause of cancer-related mortality worldwide. Antibody drug conjugates (ADCs) are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival. ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy. Currently, only two ADCs [brentuximab vedotin and trastuzumab emtansine (T-DM1)] have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer, respectively. Clinical research evaluating ADCs in GI cancers has shown limited success. In this review, we will retrace the relevant clinical trials investigating ADCs in GI cancers, especially ADCs targeting human epidermal growth receptor 2, mesothelin, guanylyl cyclase C, carcinogenic antigen-related cell adhesion molecule 5 (also known as CEACAM5) and other GI malignancy specific targets.
    [Show full text]
  • Immunotherapy in Various Cancers
    © 2021 JETIR June 2021, Volume 8, Issue 6 www.jetir.org (ISSN-2349-5162) Immunotherapy in various Cancers Nirav Parmar 1st Year MSc Student Department of Biosciences and Bioengineering, IIT- Roorkee India Abstract: Immunotherapy in the metastatic situation has changed the therapeutic landscape for a variety of cancers, including colorectal cancer. Immunotherapy has firmly established itself as a new pillar of cancer treatment in a variety of cancer types, from the metastatic stage to adjuvant and neoadjuvant settings. Immune checkpoint inhibitors have risen to prominence as a treatment option based on a better knowledge of the development of the tumour microenvironment immune cell-cancer cell regulation over time. Immunotherapy has lately appeared as the most potential field of cancer research by increasing effectiveness and reducing side effects, with FDA-approved therapies for more than 10 various tumours and thousands of new clinical studies. Key Words: Immunotherapy, metastasis, immune checkpoint. Introduction: In the late 1800s, William B. Coley, now generally regarded as the founder of immunotherapy, tried to harness the ability of immune system to cure cancer for the first time. Coley began injecting live and attenuated bacteria like Streptococcus pyogenes and Serratia marcescens into over a thousand patients in 1891 in the hopes of causing sepsis and significant immunological and antitumor responses. His bacterium mixture became known as "Coley's toxin" and is the first recorded active cancer immunotherapy treatment [1]. To better understand the processes of new and traditional immunological targets, the relationship between the immune system and tumour cells should be examined. Tumours have developed ways to evade immunological responses.
    [Show full text]
  • Deciphering Molecular Mechanisms and Prioritizing Therapeutic Targets in Cardio-Oncology
    Figure 1. This is a pilot view to explore the potential of EpiGraphDB to inform us about proteins that are linked to the pathophysiology of cancer and cardiovascular disease (CVD). For each cancer type (pink diamonds), we searched for cancer related proteins (light blue circles) that interact with other proteins identified as protein quantitative trait loci (pQTLs) for CVD (red diamonds for pathologies, orange triangles for risk factors). These pQTLs can be acting in cis (solid lines) or trans-acting (dotted lines). Proteins can interact either directly, a protein-protein interaction (dotted blue edges), or through the participation in the same pathway (red parallel lines). Shared pathways are represented with blue hexagons. We also queried which of these proteins are targeted by existing drugs. We found that the cancer drug cetuximab (yellow circle) inhibits EGFR. Other potential drugs are depicted in light brown hexagonal meta-nodes that are detailed below. Deciphering molecular mechanisms and prioritizing therapeutic targets in cardio-oncology Pau Erola1,2, Benjamin Elsworth1,2, Yi Liu2, Valeriia Haberland2 and Tom R Gaunt1,2,3 1 CRUK Integrative Cancer Epidemiology Programme; 2 MRC Integrative Epidemiology Unit, University of Bristol; 3 The Alan Turing Institute Cancer and cardiovascular disease (CVD) make by far the immense What is EpiGraphDB? contribution to the totality of human disease burden, and although mortality EpiGraphDB is an analytical platform and graph database that aims to is declining the number of those living with the disease shows little address the necessity of innovative and scalable approaches to harness evidence of change (Bhatnagar et al., Heart, 2016).
    [Show full text]
  • CNTO 888) Concentration Time Data
    Pharmacokinetics and Pharmacodynamics The Journal of Clinical Pharmacology Utilizing Pharmacokinetics/Pharmacodynamics 53(10) 1020–1027 ©2013, The American College of Modeling to Simultaneously Examine Clinical Pharmacology DOI: 10.1002/jcph.140 Free CCL2, Total CCL2 and Carlumab (CNTO 888) Concentration Time Data Gerald J. Fetterly, PhD1, Urvi Aras, PhD1, Patricia D. Meholick, MS1, Chris Takimoto, MD, PhD2, Shobha Seetharam, PhD2, Thomas McIntosh, MS2, Johann S. de Bono, MD, PhD3, Shahneen K. Sandhu, MD3, Anthony Tolcher, MD4, Hugh M. Davis, PhD2, Honghui Zhou, PhD, FCP2, and Thomas A. Puchalski, PharmD2 Abstract The chemokine ligand 2 (CCL2) promotes angiogenesis, tumor proliferation, migration, and metastasis. Carlumab is a human IgG1k monoclonal antibody with high CCL2 binding affinity. Pharmacokinetic/pharmacodynamic data from 21 cancer patients with refractory tumors were analyzed. The PK/PD model characterized the temporal relationships between serum concentrations of carlumab, free CCL2, and the carlumab–CCL2 complex. Dose‐dependent increases in total CCL2 concentrations were observed and were consistent with shifting free CCL2. Free CCL2 declined rapidly after the initial carlumab infusion, returned to baseline within 7 days, and increased to levels greater than baseline following subsequent doses. Mean predicted half‐lives of carlumab and carlumab–CCL2 complex were approximately 2.4 days and approximately 1 hour for free CCL2. The mean dissociation constant (KD), 2.4 nM, was substantially higher than predicted by in vitro experiments,
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • Preclinical Efficacy of an Antibody–Drug Conjugate Targeting
    Published OnlineFirst October 19, 2016; DOI: 10.1158/1535-7163.MCT-16-0449 Large Molecule Therapeutics Molecular Cancer Therapeutics Preclinical Efficacy of an Antibody–Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET Anton G.T. Terwisscha van Scheltinga1,2, Annie Ogasawara1, Glenn Pacheco1, Alexander N. Vanderbilt1, Jeff N. Tinianow1, Nidhi Gupta1, Dongwei Li1, Ron Firestein1, Jan Marik1, Suzie J. Scales1, and Simon-Peter Williams1 Abstract Antibody–drug conjugates (ADC) use monoclonal antibo- and HPAF-II, or mesothelioma MSTO-211H. Ex vivo analysis dies (mAb) as vehicles to deliver potent cytotoxic drugs selec- of mesothelin expression was performed using immunohis- tively to tumor cells expressing the target. Molecular imaging tochemistry. AMA-MMAE showed the greatest growth inhibi- with zirconium-89 (89Zr)-labeled mAbs recapitulates similar tion in OVCAR-3Â2.1, Capan-2, and HPAC tumors, which targeting biology and might help predict the efficacy of these showed target-specific tumor uptake of 89Zr-AMA. The less ADCs. An anti-mesothelin antibody (AMA, MMOT0530A) was responsive xenografts (AsPC-1, HPAF-II, and MSTO-211H) did used to make comparisons between its efficacy as an ADC and not show 89Zr-AMA uptake despite confirmed mesothelin its tumor uptake as measured by 89Zr immunoPET imaging. expression. ImmunoPET can demonstrate the necessary deliv- Mesothelin-targeted tumor growth inhibition by monomethyl ery, binding, and internalization of an ADC antibody in vivo auristatin E (MMAE), ADC AMA-MMAE (DMOT4039A), andthiscorrelateswiththeefficacy of mesothelin-targeted ADC was measured in mice bearing xenografts of ovarian cancer in tumors vulnerable to the cytotoxic drug delivered. Mol Cancer OVCAR-3Â2.1, pancreatic cancers Capan-2, HPAC, AsPC-1, Ther; 16(1); 134–42.
    [Show full text]
  • As a Registered E-Materials Service User of the EBMT Annual Meeting in Marseille March 26-29Th 2017, You Have Been Granted Permi
    Copyright Statement As a registered E-materials Service user of the EBMT Annual Meeting in Marseille March 26-29th 2017, you have been granted permission to access a copy of the presentation in the following pages for the purpose of scientific education. This presentation is copyrighted material and must not be copied, reproduced, transferred, distributed, leased, licensed, placed in a storage retrieval system, publicly performed or used in any way, except as specifically permitted in writing by the presenter or, as allowed under the terms and conditions under which it was received or as permitted by applicable copyright law or rules of proper citation. Any unauthorised distribution or use of this presentation, a subset of it or graphics taken from the presentation may be a direct infringement of the presenter’s rights. RACE DM training session: Immunusuppressive treatment for aplastic anemia Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples Aplastic anemia Neutrophils for Incidence, age for SCT . Opha disease. Iidee ates peset geogaphi aiatios. to ‐fold highe ates i Asia tha Euope ad the Uited States . Gloal iidee ates age .‐. ases pe illio ihaitats. Aplasti aeia: AA • AA: hat does it ea? • Ho e do the diagosis? • Whe should e teat? • Ho e teat? Aplasti aeia: AA • AA: hat does it ea? • Ho e do the diagosis? • Whe should e teat? • Ho e teat? Aplastic anemia Normal Aplastic anemia CML AA Normal Marrow aplasia Takaku et al, Blood 2010 Takaku et al, Blood 2010 Contraction of stem cell pool Cytopenia AA: hat does it ea? (Oligo) clonal CD8+ T cells Auto-immunity = immune disorder = idiopathic AA AA: hat does it ea? Constitutionnal = inherited disorder (FA, dyskeratosis congenita) Hematopoietic stem cells in AA Hematopoietic progenitor cultures T-cell clonality in aplastic anemia A surrogate marker for Ag-driven immune response Experimental Hematology 23 (1995): 433 Establishment of a CD4+ T cell clone recognizing autologous hematopoietic progenitor cells from a patient with immune-mediated aplastic anemia.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]